ARCHIVES

Conversation with The Cancer Letter: Kazerooni: The Case for Broad Coverage

This article is from The Cancer Letter archive.

Vol. 40 No. 12 | March 21, 2014

Download PDF Visit The Full Archive

Related Articles

NCI program announcement available, contract awards listed.

November 14, 2003

NCI Director and Acting FDA Commissioner Andrew von Eschenbach Endorses Rep. E. Clay Shaw In Tour of Florida Congressman’s District. Von Eschenbach Praises Shaw’s “Leadership” In Seeking Funding For Research, Support of 2015 Goal.

February 3, 2006

FDA Approves New Toxicology Protocol; Drug Program Under Fire; DCT Board Approves Cutbacks, Contract Concepts

October 9, 1981

Community Hospital Oncology Program RFP Deadline Moved Back to Sept. 5

June 22, 1979

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013

DCT Board Approves Concept of New Programs, Including “Task Order”

November 2, 1979